Company:

HMR

Hammersmith Medicines Research

Summary

Clinical Operations

Services NST provided to HMR's clients have included:

Sponsor study monitoring
Submission of clinical trial applications
Writing of clinical protocols
Writing of clinical study reports
Developing safety monitoring plans and writing safety reports

What our client said

"The HMR team has found everyone at Niche to be polite, well informed and professional in their approach. Niche has played an important role in all the projects on which it has worked, contributing in a capable fashion within the required scope and timelines. Management of the team is excellent.."

Malcolm Boyce

HMR

Request copy of the testimonial

Project background

Hammersmith Medicines Research (HMR) is a fully integrated clinical research organisation with its own purpose-designed clinical pharmacology unit. Being London-based, HMR has close ties with Central Middlesex Hospital. HMR has a broad range of expertise in complex or specialised Phase I and Phase II trials. These include trials investigating ADME, bioavailability, bioequivalence, drug-drug interactions, QT interval, and adaptive trial protocols. HMR’s central laboratory offers total pathology project management including a wide range of tests assessing safety, biomarkers, inflammation and immunological parameters.

Delivery

NST has been a trusted service provider to HMR since 2005. Over the years, NST has supported HMR’s Phase I and Phase II clinical expertise including study monitoring, submission of clinical trial applications, and medical writing for clinical protocols and study reports. NST’s broad expertise in early-phase development, project planning, high-quality writing, and clear communication proved invaluable to HMR’s investigational ethos. The NST team has integrated seamlessly with the HMR team for project delivery, establishing strong working relationships with their sponsors' companies. Notably, NST has assisted in HMR’s pharmacovigilance of vaccines and investigational drugs for rare genetic conditions, including the delivery of safety monitoring plans and DSURs. NST’s collaboration with HMR has been instrumental in the streamlined early-phase establishment of safety and tolerability, pharmacology, and preliminary efficacy of investigational drugs – paving the way for more comprehensive phase 3 studies needed for regulatory approval.